AU

Abel Ureta-Vidal

Scientist, Serial Entrepreneur, Data Strategist, Coach, Investor

Cambridge, England

Invests in

  • Min Investment:

    $10,000,000.00
  • Max Investment:

    $50,000,000.00
  • Target Investment:

    $25,000,000.00

Skills

Biotechnology
Bioinformatics
R&D
Lifesciences
Genomics
Technology Transfer
Molecular Biology
Strategy
Computational Biology
Data Analysis
Informatics
Biochemistry
Drug Discovery
Commercialization
Science
Cell Biology
Pharmaceutical Industry
Proteomics
Genetics
Clinical Development

Education

Work Experience

  • Chief Executive Officer

    2023

  • Business Strategy Adviser

    2022 - 2022

  • Member of the Long Term Sustainability Board (LTSB)

    2023

  • Venture Partner

    2021

  • Non Executive Director & Data Strategy Adviser

    2023

  • Chief Data Officer & Co-Founder

    2020 - 2023

2021 - 2024

  • Advisor

    2023 - 2024

  • Non Executive Director

    2023 - 2023

  • Mentor

    2021 - 2022

2019 - 2022

  • Member of the FAIRplus Scientific and Industry Advisory Board (SIAB)

    2019 - 2022

    https://fairplus-project.eu/ The FAIRplus is an IMI project aiming to develop tools and guidelines for making life science data FAIR (Findable, Accessible, Interoperable, Reusable)

2018 - 2022

  • Chair of the Elixir Industry Advisory Committee (IAC)

    2018 - 2022

    Chair (Jan 2020 – Jan 2022) & Vice-Chair (Jan 2018 – Jan 2020) ELIXIR is an intergovernmental organisation that brings together life science resources from across Europe.

2020 - 2021

  • Investment Director

    2020 - 2021

    The £25m investment fund established in December 2019 between China Medical System, AstraZeneca & Judge Business School to invest in innovative Life Sciences startups in the UK We invest exclusively in early UK companies in Life Sciences from as little as £10k up to £1m either alone or in syndicate. We invest in what we call the 4Ds i.e. Drugs, Devices, Diagnostics, Digital.

  • Chief Product Officer & Founder

    2018 - 2020

    • In charge of product management and updating product strategy in coordination with the rest of the management team • Providing customer facing and pre-sales support to explain long term vision and accompanying customers on their buying journeys • Participated in fund raising activity to bring on board our first VC investor (ETF) with £3m in January 2019 • Inspired the expansion of our software development workforce in India (Hyderabad) and participated in the training and on boarding of new staff there stepping our development team from 10 to 30 software developers, and the company to a total staff count of 45 • Was instrumental in finalising the partnership with Microsoft Genomics • Spire headed and implemented the opening of a commercial base in Paris at Station F to address the vibrant Life Sciences market in France and help mitigate the Brexit potential negative consequences • Opened the door to establish our New York commercial office at the Johnson&Johnson JLABS@NYC co-located with the New York Genome Centre

  • Chief Executive Officer & Founder

    2014 - 2018

    • In that period led and participated in raising a further £2.2m investment from business angel groups and small investment institutions • Reorganised and recruited a focused Senior Management team in order to implement our change in company strategy towards software products as opposed to pure services & consultancy offering. This included rethinking the company’s brand and identity and express it our marketing materials and a completely new website • Selected in the Microsoft scale up program at the Microsoft Reactor in London, as well as the Judge Business School SME Growth Challenge • Organised our product development and management team to launch our new product, eaglecore, in time and budget and convincing our first paying customer, Procter & Gamble, to invest in our solution. • Getting our company contracted in the high profile Genomics England 100,000 genomes project to demonstrate our eaglecore product capability in order to deliver this ambitious project

  • COO and Founder

    2011 - 2014

    • Focused on internal productivity and efficiency as well as quality of the project delivery to customers. • Set up processes to satisfy company legal requirements (Human resources, Health & Safety, ISMS ISO27001). • Supporting the first fund raising activity. Getting the company ready for auditing and due diligence that helped the company attract £1m external investment.

  • CEO and Founder

    2008 - 2011

    Set up the company from scratch with 2 business partners and brought it to nearly half a million pounds revenue in that period with 7 full time employees. Built a global customer base with clients in USA, Netherlands, Denmark, Singapore, Malaysia, Germany and UK

  • Member of the BIA Genomics Advisory Committee (GAC)

    2017 - 2020

    The BioIndustry Association (BIA) is the trade association for innovative life sciences in the UK